CytRx s Steven Kriegsman Discusses the Company s Foray into RNAi

Nov 07, 2003

Premium

At A Glance

Name: Steven Kriegsman

President, CEO — CytRx

Background: Global Genomics, majority shareholder — 2000 Kriegsman Capital Advisors, founder — 1999 The Kriegsman Group, founder — 1992 Kriegsman, Ader, & Co., founder — 1976 BS, accounting, New York University —1964

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu